A long-term contract extension has been agreed by Proteon Therapeutics and Lonza Pharma & Biotech for the commercial supply of the investigational vonapanitase’s active pharmaceutical ingredient (API).
“Proteon and Lonza have had a strong relationship for nearly a decade, and this amendment extends that relationship,” said Timothy Noyes, president and chief executive officer of Proteon. “The amendment provides Proteon with access to a top-tier manufacturing site for the long-term commercial supply of investigational vonapanitase after potential FDA approval.”
Read more: https://www.epmmagazine.com/news/proteon-and-lonza-expand-long-term-contract/